Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11226560 | 1.00 | BLM (0.62) | BLMSMN1; SMN2HIF1AESR1CA2 | |
| SCHEMBL24253146 | 1.00 | BLM (0.62) | BLMSMN1; SMN2HIF1AESR1CA2 | |
| SCHEMBL1272429 | 0.84 | SMN1; SMN2 (0.64) | BLMSMN1; SMN2HIF1ACYP1A2CYP3A4 | |
| SCHEMBL1272430 | 0.84 | SMN1; SMN2 (0.64) | BLMSMN1; SMN2HIF1ACYP1A2CYP3A4 | |
| SCHEMBL2032323 | 0.84 | SMN1; SMN2 (0.64) | BLMSMN1; SMN2HIF1ACYP1A2CYP3A4 | |
| SCHEMBL13205216 | 0.83 | BLM (0.47) | BLMSMN1; SMN2HIF1ACA2KDM4E | |
| Methane SCHEMBL28715292 | 0.82 | SMN1; SMN2 (0.62) | BLMSMN1; SMN2HIF1ACYP1A2CYP3A4 | |
| SCHEMBL22074772 | 0.81 | BLM (0.59) | BLMSMN1; SMN2HIF1AESR1CA2 | |
| SCHEMBL7387615 | 0.80 | BLM (0.67) | BLMSMN1; SMN2HIF1AESR1CA2 | |
| Methionine SCHEMBL5741332 | 0.80 | BLM (0.46) | BLMESR1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053249-B2 | Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders | PHILIPPE YVES-REMY SIMON (FR) | 2021-07-06 | — | — | US | claimed |
| US-20200216455-A1 | Proteasome Inhibiting Beta-Lactam Produrgs Useful for the Treatment of Cancer and Nurodegenerative Disorders | VITA API (FR) | 2020-07-09 | — | — | US | claimed |
| WO-2018115497-A1 | PROTEASOME INHIBITING ß-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-28 | — | — | WO | claimed |
| EP-3339291-A1 | PROTEASOME INHIBITING SS-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-27 | — | — | EP | claimed |
| CN-119120437-B | Tyrosine phenol lyase mutant and application thereof in synthesis of tyrosine derivatives | 浙江工业大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-117279889-B | Substituted fluorosulfates and uses thereof | 深圳湾实验室 | 2025-04-25 | — | — | CN | disclosed |
| CN-119120437-A | Tyrosine phenol lyase mutant and application thereof in synthesis of tyrosine derivatives | 浙江工业大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-119120437-A | Tyrosine phenol lyase mutant and application thereof in synthesis of tyrosine derivatives | 浙江工业大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-117279889-A | Substituted fluorosulfates and uses thereof | 深圳湾实验室 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023208081-A1 | SUBSTITUTED FLUOROSULFATE AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-11-02 | — | — | WO | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2018115497-A1 | PROTEASOME INHIBITING ß-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-28 | — | — | WO | disclosed |
| EP-3339291-A1 | PROTEASOME INHIBITING SS-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-27 | — | — | EP | disclosed |
| US-20130149243-A1 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| CN-102712552-A | Method for production of F-18 labeled glutamic acid derivatives | BAYER SCHERING PHARMA AG | 2012-10-03 | — | — | CN | disclosed |
| EP-2501663-A2 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | Piramal Imaging SA (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060887-A2 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | WO | disclosed |
| JP-2004215644-A | THYROSOL-PRODUCING MUTANT YEAST STRAIN HAVING HIGH PRODUCTIVITY, AND METHOD FOR PRODUCING FERMENTED ALCOHOLIC BEVERAGE USING THE YEAST | YAMAGATA PREFECTURE | 2004-08-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149243-A1 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | GLUL, SLC18A2, SLC1A2 | BLM 4750/4885SMN1; SMN2 2873/4885HIF1A 3607/4885 |
| US-11053249-B2 | Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders | PSMB5, PSMB1, PSMB11 | BLM 3109/4885SMN1; SMN2 221/4885HIF1A 3246/4885 |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | DDC, DDT, DDO | BLM 2619/4885SMN1; SMN2 983/4885HIF1A 4436/4885 |
| US-20200216455-A1 | Proteasome Inhibiting Beta-Lactam Produrgs Useful for the Treatment of Cancer and Nurodegenerative Disorders | PSMB5, PSMB1, PSMB11 | BLM 3666/4885SMN1; SMN2 96/4885HIF1A 2683/4885 |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | BLM 3756/4885SMN1; SMN2 151/4885HIF1A 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.